The adequate treatment of ovary tumor and the issue of improvement of subsequent results still remain the urgent question of oncology. In 60-80% of diseased the pathology appears at the final--the third and the forth i.e. later stages, while the prolongation of life for the five years period is quite rare--13-47%. Our aim is to study the effectiveness of treatment of malignant ovary tumor based on the data of 1990-2000 provided by A. Gvamichava National Oncological Centre, to develop optimal methods of treatment and select the right tactics in order to improve subsequent results for patients with malignant ovary tumor. The research revealed that the epithelial neoplasm (malignant ovary tumor) is 5.2 times more spread than nonepithelial (malignant ovary tumor). In our clinic the preference is given to the operational method combined with further chemotherapy (ch/t) for treatment of malignant ovary tumor. The advantage is given to the radical surgery (59.4%), amputation of uterine appendages and omentum resection (79.3%). In the case of less radical surgery (23%)--amputation of uterine appendages (63.8%), while for non-radical surgery (17.5%)--ovariectomy, omentum resection (60%). The number of radical surgery of epithelial neoplasm 3 times exceeds less radical surgery and 12 times--non-radical surgery, while in the case of non epithelial neoplasm the number of radical surgery is two times more than less radical surgery and 3 times more than that non radical. In 1990-2000 in the National Oncological Centre ch/t without platinum and audrioblastin (44.8%) had been most frequently used for treatment of ovary tumor. The main schemes were: cyclophosphan + phtoruracyle and cyclophosphan + phtoruracyle +metotrexat.
Download full-text PDF |
Source |
---|
Cancer Invest
January 2025
Psychology Department, Faculty of Philosophy, Sciences and Letters at Ribeirão Preto, University of São Paulo, Ribeirão Preto-SP, Brazil.
Although breast, cervical, endometrial, and ovarian cancers account for more than 43% of new cases in 2023 in Brazilian women, no national studies were found on the incidence, risk factors, and prevention of breast and gynecological neoplasms in lesbian women, causing the health needs of non-heterosexual women to go unnoticed by professionals. This study aims to identify and analyze the search for healthcare related to the prevention of breast/gynecological cancer among Brazilian lesbian cisgender women who have not had the disease. Seven lesbian women participated in this qualitative study.
View Article and Find Full Text PDFJ Surg Case Rep
January 2025
Department of Pathology of the National Institute of Oncology, Ibn Sina University Hospital Center, Allal Al Fassi Avenue, Rabat 10100, Morocco.
Mesonephric-like adenocarcinoma (MLA) is a rare and newly recognized subtype of ovarian and endometrial carcinomas, introduced in the 2020 World Health Organization Classification. This tumor likely originates from Müllerian-derived tissues and often mimics more common ovarian cancers, leading to frequent misdiagnosis. This case study details a 36-year-old woman who presented with urinary symptoms following a hysterectomy.
View Article and Find Full Text PDFEClinicalMedicine
February 2025
Department of Breast and Gynaecological Surgery, Institut Curie, Paris, France.
Background: Randomized clinical trials (RCTs) are fundamental to evidence-based medicine, but their real-world impact on clinical practice often remains unmonitored. Leveraging large-scale real-world data can enable systematic monitoring of RCT effects. We aimed to develop a reproducible framework using real-world data to assess how major RCTs influence medical practice, using two pivotal surgical RCTs in gynaecologic oncology as an example-the LACC (Laparoscopic Approach to Cervical Cancer) and LION (Lymphadenectomy in Ovarian Neoplasms) trials.
View Article and Find Full Text PDFCureus
December 2024
Obstetrics and Gynecology, Marunouchi Hospital, Matsumoto, JPN.
Malignant transformation is a rare complication of ovarian mature cystic teratoma that occurs in 1-3% of cases. We herein report a case of squamous cell carcinoma originating from mature cystic teratoma of the ovary diagnosed 10 years after initial tumor detection. A 69-year-old woman presented to the Department of Internal Medicine with a seven-month history of abdominal fullness.
View Article and Find Full Text PDFInt J Womens Health
January 2025
Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran-Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.
Background: Clear cell ovarian carcinoma (CCOC) is a type of epithelial ovarian cancer, representing 5-11% of ovarian cancers. CCOCs tend to occur in the fifth to seventh decades of life, with only 10% of cases occurring in the fourth decade. On the other side, papillary thyroid carcinoma is the most common histology type of thyroid carcinoma and is associated with locoregional spread.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!